Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Alvotech SA

ALVO ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$4.06

▼ -0.86%

Market Cap $1.58B · Vol 233.34K

Key Metrics

P/E Ratio

N/A

FWD: 28.25

Market Cap

$1.58B

Small Cap

Div Yield

N/A

EPS Growth

-81.43%

YoY

RSI (14)

75.06

Momentum

Beta

0.16

vs Market

52W High

$9.25

56.16% below

52W Low

$2.95

37.69% above

Volume

233.34K

Avg 184.97K

P/B

N/A

Price-to-book

ROE

-30.97%

Return on equity

Free Float

45.12%

Public shares

Shariah Compliance8 STANDARDS

✗ Alvotech SA (ALVO) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ALVO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.43%

+22.88%

+18.22%

-12.61%

YTD

-20.96%

-52.15%

-54.18%

-58.66%

Financials & Valuation

TTM · Annual

Total Revenue	$588.90M
Net Income	$27.92M
Revenue Growth (YoY)	-20.23%
Gross Margin	60.00%
Operating Margin	15.62%
Net Profit Margin	4.74%
ROE	-30.97%
ROA · ROIC	10.07% · 5.76%

P/E Ratio	N/A
Forward P/E (FY1)	28.25
PEG Ratio	0.48
P/S	2.54
P/B	N/A
P/FCF	N/A
EPS Growth	-81.43%
Outstanding Shares	390.43M

Technical Indicators

50-Day SMA	$3.67
200-Day SMA	$4.24
RSI (14)	75.06
Beta	0.16
52-Week High	$9.25
52-Week Low	$2.95

Volume Today	233.34K
Avg Daily Volume (30D)	184.97K
Relative Volume	1.26x
Volatility (10D)	52.94
Volatility (30D)	74.62
Free Float	45.12%

Analyst Consensus

BUY

Current Price $4.06

Mean Target $6.50

52W Low$2.95 52W High$9.25

Current

Target

$2.95 $9.25

Current Analyst target

+60.30% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG014MBMZZ1

ISINLU2458332611

CountryLuxembourg

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateAug 19, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.